• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期持续存在 MHC Ⅰ类限制性 TCR 具有纳摩尔亲和力的 CD4(+)T 细胞,但 CD8(+)T 细胞迅速消失。

Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.

机构信息

Department of Pathology, Committee on Immunology, The University of Chicago, Chicago, Illinois 60637-5420, USA.

出版信息

Mol Ther. 2012 Mar;20(3):652-60. doi: 10.1038/mt.2011.286. Epub 2012 Jan 10.

DOI:10.1038/mt.2011.286
PMID:22233579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3293607/
Abstract

Most T cells have T cell receptors (TCR) of micromolar affinity for peptide-major histocompatibility complex (MHC) ligands, but genetic engineering can generate TCRs of nanomolar affinity. The affinity of the TCR used, m33, for its cognate non-self peptide-MHC-I complex (SIYRYYGL-K(b)) is 1,000-fold higher than of the wild-type TCR 2C. The affinity of m33 for the self-peptide dEV-8 on K(b) is only twofold higher. Mouse CD8(+) T cells transduced with an m33-encoding retrovirus showed binding of SIY-K(b) and potent function in vitro, but in vivo these T cells disappeared within hours after transfer into syngeneic hosts without causing graft-versus-host disease (GVHD). Accordingly, in cases where such CD8-dependent self-reactivity might occur in human adoptive T cell therapies, our results show that a peripheral T-cell deletion mechanism could operate to avoid reactions with the host. In contrast to CD8(+) T cells, we show that CD4(+) T cells expressing m33 survived for months in vivo. Furthermore, the m33-transduced CD4(+) T cells were able to mediate antigen-specific rejection of 6-day-old tumors. Together, we show that CD8(+) T cell expressing a MHC class I-restricted high-affinity TCR were rapidly deleted whereas CD4(+) T cells expressing the same TCR survived and provided function while being directed against a class I-restricted antigen.

摘要

大多数 T 细胞的 T 细胞受体 (TCR) 对肽-主要组织相容性复合体 (MHC) 配体的亲和力为微摩尔级,但基因工程可以产生纳摩尔级亲和力的 TCR。所使用的 TCR(m33)与其同源非自身肽-MHC-I 复合物(SIYRYYGL-K(b))的亲和力比野生型 TCR 2C 高 1000 倍。m33 与 K(b) 上自身肽 dEV-8 的亲和力仅高出两倍。用编码 m33 的逆转录病毒转导的小鼠 CD8(+) T 细胞显示出对 SIY-K(b)的结合和体外强大的功能,但在体内,这些 T 细胞在转移到同基因宿主后数小时内消失,而不会引起移植物抗宿主病 (GVHD)。因此,在人类过继性 T 细胞治疗中可能发生这种 CD8 依赖性自身反应的情况下,我们的结果表明,外周 T 细胞删除机制可能会发挥作用,以避免与宿主发生反应。与 CD8(+) T 细胞相反,我们表明表达 m33 的 CD4(+) T 细胞在体内存活了数月。此外,转导 m33 的 CD4(+) T 细胞能够介导针对 6 天龄肿瘤的抗原特异性排斥。总之,我们表明表达 MHC Ⅰ类限制性高亲和力 TCR 的 CD8(+) T 细胞迅速被删除,而表达相同 TCR 的 CD4(+) T 细胞存活并提供功能,同时针对 I 类限制性抗原。

相似文献

1
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.长期持续存在 MHC Ⅰ类限制性 TCR 具有纳摩尔亲和力的 CD4(+)T 细胞,但 CD8(+)T 细胞迅速消失。
Mol Ther. 2012 Mar;20(3):652-60. doi: 10.1038/mt.2011.286. Epub 2012 Jan 10.
2
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.MHC Ⅰ类限制性 CD4 T 细胞:与微摩尔野生型 TCR 相比,纳米摩尔亲和力 TCR 具有改善的体内抗肿瘤疗效。
Cancer Immunol Immunother. 2013 Feb;62(2):359-69. doi: 10.1007/s00262-012-1336-z. Epub 2012 Aug 25.
3
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.用于临床前过继免疫治疗研究的小鼠 CD8+和 CD4+ T 细胞的基因工程。
J Immunother. 2011 May;34(4):343-52. doi: 10.1097/CJI.0b013e3182187600.
4
Cross-positive selection of thymocytes expressing a single TCR by multiple major histocompatibility complex molecules of both classes: implications for CD4+ versus CD8+ lineage commitment.两类主要组织相容性复合体分子对表达单一T细胞受体的胸腺细胞进行交叉阳性选择:对CD4⁺与CD8⁺谱系定向分化的影响
J Immunol. 2006 Feb 1;176(3):1628-36. doi: 10.4049/jimmunol.176.3.1628.
5
Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses.设计具有多样化结合特性的 T 细胞受体文库,以研究过继性 T 细胞反应。
Gene Ther. 2013 Jun;20(6):634-44. doi: 10.1038/gt.2012.80. Epub 2012 Oct 11.
6
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.转导以表达MHC I类限制性表位特异性TCR的CD4+CD25-T细胞在人黑色素瘤模型中合成Th1细胞因子并表现出MHC I类限制性细胞溶解效应功能。
J Immunol. 2008 Jul 15;181(2):1063-70. doi: 10.4049/jimmunol.181.2.1063.
7
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.当用靶向酪氨酸酶的高亲和性 TCR 工程改造时,CD4 和 CD8 T 细胞在体内肿瘤治疗中具有同等的有效性。
J Immunol. 2010 Jun 1;184(11):5988-98. doi: 10.4049/jimmunol.1000189. Epub 2010 Apr 28.
8
Human leucocyte antigen class I-redirected anti-tumour CD4 T cells require a higher T cell receptor binding affinity for optimal activity than CD8 T cells.与CD8 T细胞相比,人白细胞抗原I类重定向抗肿瘤CD4 T细胞需要更高的T细胞受体结合亲和力才能实现最佳活性。
Clin Exp Immunol. 2017 Jan;187(1):124-137. doi: 10.1111/cei.12828. Epub 2016 Nov 14.
9
A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.一种罕见的肿瘤抗原特异性 CD4CD8 双阳性 αβ T 淋巴细胞群体,为工程化治疗性 T 细胞提供了独特的 CD8 非依赖性 TCR 基因。
J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.
10
CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.仅针对微小组织相容性抗原介导移植物抗宿主病(GVHD)时,CD8⁺而非CD4⁺T细胞需要与靶组织进行同源相互作用,而CD4⁺和CD8⁺T细胞介导移植物抗白血病效应(GVL)均需要与白血病细胞直接接触。
Blood. 2008 Apr 1;111(7):3884-92. doi: 10.1182/blood-2007-11-125294. Epub 2008 Jan 25.

引用本文的文献

1
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.天然 TCR 靶向 KRASG12V 对人类实体肿瘤具有良好的特异性和敏感性。
J Clin Invest. 2024 Sep 17;134(21):e175790. doi: 10.1172/JCI175790.
2
CD4 T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.具有趋同 TCR 重组的 CD4 T 细胞重编程基质并在过继治疗中阻止肿瘤进展。
Sci Immunol. 2024 Sep 13;9(99):eadp6529. doi: 10.1126/sciimmunol.adp6529.
3
The landscape of T cell antigens for cancer immunotherapy.癌症免疫治疗的 T 细胞抗原全景。
Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6.
4
OX40 as a novel target for the reversal of immune escape in colorectal cancer.OX40作为逆转结直肠癌免疫逃逸的新靶点。
Am J Transl Res. 2021 Mar 15;13(3):923-934. eCollection 2021.
5
Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.开发一种针对肿瘤相关抗原 MAGE-A4 的 CD8 共受体非依赖性 T 细胞受体,用于下一代基于 T 细胞的免疫治疗。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002035.
6
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.嵌合抗原受体 T 细胞疗法治疗儿童和青年 B 细胞急性淋巴细胞白血病。
Expert Rev Clin Immunol. 2020 Oct;16(10):1029-1042. doi: 10.1080/1744666X.2021.1828067.
7
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.工程策略增强 TCR 为基础的过继性 T 细胞治疗。
Cells. 2020 Jun 18;9(6):1485. doi: 10.3390/cells9061485.
8
Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.慢性 TCR-MHC(自身)相互作用限制了 TCR 亲和力增加的 CD8 T 淋巴细胞的功能潜力。
J Immunother Cancer. 2019 Nov 5;7(1):284. doi: 10.1186/s40425-019-0773-z.
9
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.过继性T细胞疗法中用于基因转移的T细胞受体
Crit Rev Immunol. 2019;39(2):105-122. doi: 10.1615/CritRevImmunol.2019030788.
10
Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.通过结构导向设计提高 T 细胞受体的靶标特异性。
Mol Ther. 2019 Feb 6;27(2):300-313. doi: 10.1016/j.ymthe.2018.12.010. Epub 2018 Dec 14.

本文引用的文献

1
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.CD4+ T 细胞在肿瘤微环境中的辅助作用对于 CD8+ T 淋巴细胞的募集和细胞溶解功能是必需的。
Cancer Res. 2010 Nov 1;70(21):8368-77. doi: 10.1158/0008-5472.CAN-10-1322. Epub 2010 Oct 12.
2
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.旁观者效应杀伤肿瘤需要效应期 CD4(+)和 CD8(+)T 细胞的协同作用。
J Exp Med. 2010 Oct 25;207(11):2469-77. doi: 10.1084/jem.20092450. Epub 2010 Oct 4.
3
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.经 T 细胞受体基因转导生成的人抗原特异性调节 T 细胞。
PLoS One. 2010 Jul 22;5(7):e11726. doi: 10.1371/journal.pone.0011726.
4
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.T 细胞受体基因治疗的小鼠模型中的致命移植物抗宿主病。
Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18.
5
Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.淋巴结驻留的淋巴管内皮细胞通过非 Aire 依赖的直接抗原呈递介导外周耐受。
J Exp Med. 2010 Apr 12;207(4):681-8. doi: 10.1084/jem.20092465. Epub 2010 Mar 22.
6
Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions.在稳态和炎症条件下,淋巴结纤维母细胞网状细胞直接呈递外周组织抗原。
J Exp Med. 2010 Apr 12;207(4):689-97. doi: 10.1084/jem.20092642. Epub 2010 Mar 22.
7
Mechanisms maintaining peripheral tolerance.维持外周耐受的机制。
Nat Immunol. 2010 Jan;11(1):21-7. doi: 10.1038/ni.1817. Epub 2009 Dec 17.
8
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help.CD8(+) T 淋巴细胞向病毒感染组织的迁移需要 CD4(+) T 细胞的辅助。
Nature. 2009 Nov 26;462(7272):510-3. doi: 10.1038/nature08511. Epub 2009 Nov 8.
9
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.T细胞受体结合特性和抗原呈递形式对T细胞反应性的影响。
J Immunol. 2009 Jul 15;183(2):1166-78. doi: 10.4049/jimmunol.0900054. Epub 2009 Jun 24.
10
Transcriptional regulation by AIRE: molecular mechanisms of central tolerance.由自身免疫调节因子(AIRE)介导的转录调控:中枢耐受的分子机制
Nat Rev Immunol. 2008 Dec;8(12):948-57. doi: 10.1038/nri2450.